MCID: OCL022
MIFTS: 52

Ocular Melanoma malady

Categories: Rare diseases, Cancer diseases, Neuronal diseases, Eye diseases, Skin diseases

Aliases & Classifications for Ocular Melanoma

Aliases & Descriptions for Ocular Melanoma:

Name: Ocular Melanoma 12 50 52 14
Intraocular Melanoma 12 50 29
Uveal Melanoma 50 69
Malignant Melanoma of Eye 69
Melanoma of the Uvea 50
Melanoma of Eye 12
Eye Melanoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1752

Summaries for Ocular Melanoma

NIH Rare Diseases : 50 intraocular melanoma is a cancer of the pigment-producing cells (melanocytes) in the middle layer of the eye, called the uveal tract.  the uveal tract has 3 main parts: (1) the choroid (the tissue layer filled with blood vessels); (2) the ciliary body (the ring of muscle tissue that changes the size of the pupil and the shape of the lens); and (3) the iris (the colored part of the eye). most cases (90%) of intraocular melanoma develop in the choroid, called choroidal melanoma; the ciliary body is less commonly a site of origin, and the iris is the least common.  each manifests with different clinical features and symptoms. treatment depends on the site of origin (choroid, ciliary body, or iris), size and location of the tumor, the age of the individual, and other factors.  last updated: 11/29/2010

MalaCards based summary : Ocular Melanoma, also known as intraocular melanoma, is related to bap1 tumor predisposition syndrome and choroid spindle cell melanoma. An important gene associated with Ocular Melanoma is MC1R (Melanocortin 1 Receptor), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Glioma. The drugs Ranibizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and testes, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 An ocular cancer that has material basis in melanocytes and is located in the eye.

Related Diseases for Ocular Melanoma

Diseases related to Ocular Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
id Related Disease Score Top Affiliating Genes
1 bap1 tumor predisposition syndrome 11.0
2 choroid spindle cell melanoma 10.9
3 ciliary body spindle cell melanoma 10.9
4 iris spindle cell melanoma 10.9
5 melanoma 10.8
6 eccrine sweat gland neoplasm 10.3 BAP1 BRCA2
7 sarcoma 10.2 IL2 KIT
8 spinal cord melanoma 10.2 IL2 KIT
9 bacteremia 10.2 BAP1 BRCA2
10 endometrial disease 10.2 BRCA2 CDKN2A
11 facial nerve disease 10.2 BAP1 NRAS
12 fallopian tube adenofibroma 10.2 BAP1 NRAS
13 paraphimosis 10.2 BRCA2 CDKN2A
14 primary tubular proximal acidosis 10.2 CDKN2A IL2
15 louse-borne relapsing fever 10.2 CDKN2A IL2
16 hepatitis 10.2
17 vulva basal cell carcinoma 10.2 CDKN2A KIT
18 parotid gland adenoid cystic carcinoma 10.2 KIT NRAS
19 choroiditis 10.2
20 fragile x-associated tremor/ataxia syndrome 10.2 CDKN2A KIT
21 verrucous papilloma 10.1 KIT NRAS
22 barbiturate dependence 10.1 CDKN2A IL2
23 cerebral arterial disease 10.1 KIT NRAS
24 pancreatic invasive mucinous cystadenocarcinoma 10.1 BRCA2 CDKN2A
25 aortic aneurysm 10.1 CDKN2A VEGFA
26 gallbladder pleomorphic giant cell adenocarcinoma 10.1 CDKN2A NRAS
27 post-surgical hypoinsulinemia 10.1 BRCA2 CDKN2A IL2
28 neurocutaneous melanosis, somatic 10.1 MC1R NRAS
29 diffuse glomerulonephritis 10.1 KIT NRAS
30 adult epithelioid sarcoma 10.1 CDKN2A NRAS
31 lung mucoepidermoid carcinoma 10.0 IL2 KIT NRAS
32 factitious disorder 10.0 KIT VEGFA
33 ossifying fibromyxoid tumor 10.0 CDKN2A NRAS
34 acute disseminated encephalomyelitis 10.0 CDKN2A KIT NRAS
35 vulval paget's disease 10.0 CDKN2A KIT NRAS
36 nelson syndrome 10.0 CDKN2A KIT NRAS
37 vaginal endometrial stromal sarcoma 10.0 BAP1 CDKN2A VEGFA
38 vulvar proximal-type epithelioid sarcoma 10.0 BAP1 CDKN2A VEGFA
39 hemophagocytic lymphohistiocytosis 10.0 IL2 KIT VEGFA
40 trachea squamous cell carcinoma 10.0 BRCA2 CDKN2A VEGFA
41 bardet-biedl syndrome 10.0 BRCA2 CDKN2A VEGFA
42 uterine corpus leiomyomatosis 10.0 CDKN2A NRAS
43 nevoid hypermelanosis, linear and whorled 10.0 BRCA2 CDKN2A VEGFA
44 glucosephosphate isomerase deficiency 10.0 CDKN2A IL2 VEGFA
45 proctitis 10.0 CDKN2A KIT VEGFA
46 gastrointestinal stromal tumor 9.9 CDKN2A KIT VEGFA
47 tumor of exocrine pancreas 9.9 CDKN2A VEGFA
48 ectopic thymus 9.9 CIITA IL2
49 extranodal nasal nk/t cell lymphoma 9.9 CDKN2A KIT
50 ladd syndrome 9.9 CDKN2A IL2 VEGFA

Graphical network of the top 20 diseases related to Ocular Melanoma:



Diseases related to Ocular Melanoma

Symptoms & Phenotypes for Ocular Melanoma

MGI Mouse Phenotypes related to Ocular Melanoma:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 BAP1 VEGFA BRCA2 CDKN2A IL2 KIT
2 hematopoietic system MP:0005397 10.16 BRCA2 CDKN2A CIITA IL2 KIT MC1R
3 endocrine/exocrine gland MP:0005379 10.14 BAP1 BRCA2 CDKN2A CIITA IL2 KIT
4 growth/size/body region MP:0005378 10.13 BAP1 BRCA2 CDKN2A IL2 KIT MC1R
5 immune system MP:0005387 10.13 BAP1 BRCA2 CDKN2A CIITA IL2 KIT
6 behavior/neurological MP:0005386 10.12 BRCA2 CDKN2A IL2 KIT MC1R NRAS
7 digestive/alimentary MP:0005381 10.1 BAP1 BRCA2 CDKN2A IL2 KIT NRAS
8 homeostasis/metabolism MP:0005376 10.1 BAP1 BRCA2 CDKN2A CIITA IL2 KIT
9 embryo MP:0005380 10.02 BAP1 BRCA2 CDKN2A KIT NRAS VEGFA
10 integument MP:0010771 10 BAP1 BRCA2 CDKN2A KIT MC1R NRAS
11 neoplasm MP:0002006 9.97 BAP1 BRCA2 CDKN2A IL2 KIT MC1R
12 no phenotypic analysis MP:0003012 9.87 KIT MC1R NRAS VEGFA BAP1 CDKN2A
13 limbs/digits/tail MP:0005371 9.83 BRCA2 KIT MC1R NRAS VEGFA
14 liver/biliary system MP:0005370 9.8 CDKN2A IL2 KIT NRAS VEGFA
15 normal MP:0002873 9.73 PDCD6 VEGFA BRCA2 CIITA KIT NRAS
16 pigmentation MP:0001186 9.46 CDKN2A KIT MC1R NRAS
17 reproductive system MP:0005389 9.43 BAP1 BRCA2 CDKN2A IL2 KIT VEGFA
18 respiratory system MP:0005388 9.02 CDKN2A IL2 KIT VEGFA BAP1

Drugs & Therapeutics for Ocular Melanoma

Drugs for Ocular Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 259)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 124-94-7 31307
3 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
4 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
5 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
6 glucocorticoids Phase 4,Phase 2,Phase 3
7 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
8 Hormones Phase 4,Phase 2,Phase 3,Phase 1
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
10 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
11 triamcinolone acetonide Phase 4,Phase 2,Phase 3
12 Triamcinolone diacetate Phase 4,Phase 2,Phase 3
13 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3
14
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
15
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
16
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
17
Melphalan Approved Phase 3,Phase 2 148-82-3 4053 460612
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Aldesleukin Approved Phase 3,Phase 1,Phase 2,Early Phase 1 85898-30-2, 110942-02-4
20
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
21
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
22
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
23
Morphine Approved, Investigational Phase 3 57-27-2 5288826
24
Pembrolizumab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 1374853-91-4
25
nivolumab Approved Phase 2, Phase 3,Phase 1,Early Phase 1 946414-94-4
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
27
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 59-67-6 938
28
Nicotinamide Approved, Nutraceutical Phase 3,Phase 2,Phase 1 98-92-0 936
29
Fotemustine Experimental Phase 3,Phase 2
30 Adjuvants, Immunologic Phase 3,Phase 1,Phase 2
31
QS 21 Phase 3 141256-04-4
32 Vaccines Phase 3,Phase 2,Phase 1
33 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
35 Liver Extracts Phase 3,Phase 1,Phase 2,Early Phase 1
36 Analgesics Phase 3,Phase 1,Phase 2,Early Phase 1
37 Analgesics, Opioid Phase 3,Phase 1,Phase 2
38 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
39 Narcotics Phase 3,Phase 1,Phase 2
40 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2,Early Phase 1
41 Freund's Adjuvant Phase 3,Phase 1,Phase 2
42 Analgesics, Non-Narcotic Phase 3,Phase 1,Phase 2,Early Phase 1
43 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
44 Antiviral Agents Phase 3,Phase 2,Phase 1
45 Micronutrients Phase 3,Phase 2,Phase 1
46 Nicotinic Acids Phase 3,Phase 2,Phase 1
47 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
48 Trace Elements Phase 3,Phase 2,Phase 1
49 Vitamin B Complex Phase 3,Phase 2,Phase 1
50 Vitamins Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 350)
id Name Status NCT ID Phase
1 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
2 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4
3 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3
4 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
5 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
6 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3
7 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
9 An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma Completed NCT01368276 Phase 3
10 Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma Completed NCT00072124 Phase 3
11 Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma Completed NCT01989572 Phase 3
12 Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma Completed NCT00019682 Phase 3
13 Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00110019 Phase 3
14 Evaluation of Pigmented Skin Lesions With MelaFind(R) System Completed NCT00434057 Phase 3
15 Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases Completed NCT00540969 Phase 3
16 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
17 Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Recruiting NCT01983748 Phase 3
18 The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases Recruiting NCT01785316 Phase 3
19 Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma Recruiting NCT02678572 Phase 3
20 Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) Recruiting NCT02821013 Phase 3
21 Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma Recruiting NCT01826864 Phase 3
22 Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Recruiting NCT02339571 Phase 2, Phase 3
23 Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Active, not recruiting NCT02843386 Phase 3
24 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Active, not recruiting NCT01274338 Phase 3
25 Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy Active, not recruiting NCT01223248 Phase 3
26 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3
27 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3
28 Vaccine Therapy in Treating Patients With Melanoma of the Eye Terminated NCT00036816 Phase 3
29 A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma Terminated NCT01006252 Phase 3
30 High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma Terminated NCT00003641 Phase 3
31 Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases Terminated NCT00581113 Phase 3
32 High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma Withdrawn NCT00447356 Phase 3
33 A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Unknown status NCT01377025 Phase 2
34 Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Unknown status NCT01034787 Phase 2
35 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2
36 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2
37 Study of Metastatic Ocular Melanoma Unknown status NCT00168870 Phase 2
38 Pain Relief - Tramadol Versus Ibuprofen Unknown status NCT00111046 Phase 1, Phase 2
39 Vaccine Therapy in Treating Patients With Malignant Melanoma Unknown status NCT00128583 Phase 2
40 Vaccine Therapy in Treating Patients With Stage IV Melanoma Unknown status NCT00126685 Phase 1, Phase 2
41 Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma Unknown status NCT00118274 Phase 1, Phase 2
42 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery Unknown status NCT00086866 Phase 2
43 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Unknown status NCT00085397 Phase 2
44 Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma Unknown status NCT00538005 Phase 1, Phase 2
45 Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer Unknown status NCT00553683 Phase 1, Phase 2
46 Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma Completed NCT00506142 Phase 2
47 RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Completed NCT01252251 Phase 2
48 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery Completed NCT00738361 Phase 2
49 Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Completed NCT02517736 Phase 2
50 Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Completed NCT00661622 Phase 2

Search NIH Clinical Center for Ocular Melanoma

Genetic Tests for Ocular Melanoma

Genetic tests related to Ocular Melanoma:

id Genetic test Affiliating Genes
1 Intraocular Melanoma 29

Anatomical Context for Ocular Melanoma

MalaCards organs/tissues related to Ocular Melanoma:

39
Eye, Liver, Testes, Skin, Nk Cells, Lymph Node, Pancreas

The Foundational Model of Anatomy Ontology organs/tissues related to Ocular Melanoma:

18
The Eye

Publications for Ocular Melanoma

Articles related to Ocular Melanoma:

(show top 50) (show all 328)
id Title Authors Year
1
Comment on "Milham & Stetzer (2016) Tumor-specific frequencies and ocular melanoma." Electromag Biol Med http://dx.doi.org/10.1080/15368378.2016.1234390. ( 27715332 )
2017
2
Tumor-specific frequencies and ocular melanoma. ( 27552371 )
2016
3
Metastatic Ocular Melanoma to the Liver Exhibits Infiltrative and Nodular Growth Patterns. ( 27476775 )
2016
4
Overexpression of hepatocyte growth factor and an oncogenic CDK4 variant in mice alters corneal stroma morphology but does not lead to spontaneous ocular melanoma. ( 26731561 )
2016
5
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. ( 27520988 )
2016
6
Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques. ( 27475484 )
2016
7
The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. ( 26655090 )
2016
8
EPIDEMIOLOGICAL ANALYSIS OF OCULAR MELANOMA IN UNIVERSITY CLINIC CENTER IN TUZLA, BOSNIA AND HERZEGOVINA. ( 27698609 )
2016
9
Imaging of ocular melanoma metastasis. ( 27168029 )
2016
10
Feasibility of Proton Beam Therapy for Ocular Melanoma Using a Novel 3D Treatment Planning Technique. ( 27084652 )
2016
11
Metastatic melanoma after 23a88years of primary ocular melanoma. ( 27881589 )
2016
12
Head and neck melanoma (excluding ocular melanoma): United Kingdom National Multidisciplinary Guidelines. ( 27841141 )
2016
13
Diffusion-weighted magnetic resonance imaging for predicting and detecting the response of ocular melanoma to proton beam therapy: initial results. ( 25578783 )
2015
14
A challenging case of ocular melanoma. ( 26429178 )
2015
15
Nationwide Incidence of Ocular Melanoma in South Korea by Using the National Cancer Registry Database (1999-2011). ( 26207308 )
2015
16
Dynamic contrast-enhanced MRI of ocular melanoma. ( 25714038 )
2015
17
Heterogeneous dose calculations for Collaborative Ocular Melanoma Study eye plaques using actual seed configurations and Task Group Report 43 formalism. ( 25533415 )
2015
18
Metastatic Ocular Melanoma Presenting as a Heart-Compressing Mediastinal Mass. ( 26434443 )
2015
19
Low thyroid hormone levels improve survival in murine model for ocular melanoma. ( 25868390 )
2015
20
Effects of defining realistic compositions of the ocular melanoma on proton therapy. ( 25599060 )
2014
21
Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma. ( 25207419 )
2014
22
Evidence-based integration of selective internal radiation therapy into the management of ocular melanoma liver metastases. ( 25478778 )
2014
23
Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist. ( 24697775 )
2014
24
Ocular melanoma: an overview of the current status. ( 23826405 )
2013
25
Diffusion-weighted imaging of ocular melanoma. ( 23614974 )
2013
26
Combined surgical resection and radiofrequency ablation as treatment for metastatic ocular melanoma. ( 22766897 )
2013
27
Ocular melanoma metastasizing to intra-abdominal lymph nodes. ( 23762736 )
2013
28
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. ( 23799844 )
2013
29
Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture. ( 23392528 )
2013
30
Isolated Hepatic Perfusion for Ocular Melanoma Metastasis: Registry Data Suggests a Survival Benefit. ( 24141377 )
2013
31
Left ventricular metastasis from ocular melanoma: a new, rare, and unusual pathway? ( 23816109 )
2013
32
Solitary secondary malignant melanoma of clavicle two years after enuclation for ocular melanoma. ( 23424696 )
2013
33
Pretherapeutic laboratory findings, extent of metastasis and choice of treatment as prognostic markers in ocular melanoma- a single centre experience. ( 23057648 )
2013
34
SECONDARY NEUTRON DOSES IN PROTON THERAPY TREATMENTS OF OCULAR MELANOMA AND CRANIOPHARYNGIOMA. ( 24222710 )
2013
35
The Collaborative Ocular Melanoma Study, mortality by therapeutic approach, age and tumor size. ( 24069782 )
2013
36
Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism? ( 22707951 )
2012
37
Ocular melanoma. ( 23960984 )
2012
38
Ocular melanoma and mammary mucinous carcinoma in an African lion. ( 23009723 )
2012
39
Ocular melanoma: what's new? ( 22234256 )
2012
40
Baker's Cyst on F-18 FDG PET/CT in a Patient with Ocular Melanoma. ( 23486655 )
2012
41
Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. ( 22545102 )
2012
42
Ocular melanoma metastasis to the cervical spine. ( 22245271 )
2012
43
Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy. ( 22207316 )
2012
44
Ocular melanoma in a patient successfully treated for diffuse malignant peritoneal mesothelioma: a case report. ( 22613358 )
2012
45
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-I_B pathways. ( 22653968 )
2012
46
Survival and complications following I^ knife radiosurgery or enucleation for ocular melanoma: a 20-year experience. ( 22231777 )
2012
47
Education and imaging. Gastrointestinal: metastatic ocular melanoma causing massive hepatomegaly. ( 21950748 )
2011
48
Collaborative ocular melanoma study randomized trial of I-125 brachytherapy. ( 22013172 )
2011
49
Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. ( 21057964 )
2011
50
KIT mutations in ocular melanoma: frequency and anatomic distribution. ( 21478825 )
2011

Variations for Ocular Melanoma

ClinVar genetic disease variations for Ocular Melanoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 GNAQ NM_002072.4(GNAQ): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh37 Chromosome 9, 80409488: 80409488
2 GNAQ NM_002072.4(GNAQ): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh37 Chromosome 9, 80409488: 80409488
3 GNA11 NM_002067.4(GNA11): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh37 Chromosome 19, 3118942: 3118942
4 GNA11 NM_002067.4(GNA11): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh37 Chromosome 19, 3118942: 3118942

Expression for Ocular Melanoma

Search GEO for disease gene expression data for Ocular Melanoma.

Pathways for Ocular Melanoma

GO Terms for Ocular Melanoma

Biological processes related to Ocular Melanoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.72 CDKN2A CIITA IL2 MC1R VEGFA
2 pigmentation GO:0043473 9.4 KIT MC1R
3 T cell differentiation GO:0030217 9.37 IL2 KIT
4 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.26 IL2 KIT
5 somatic stem cell division GO:0048103 9.16 CDKN2A KIT
6 positive regulation of protein kinase C signaling GO:0090037 8.96 MC1R VEGFA
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 8.8 IL2 KIT VEGFA

Sources for Ocular Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....